Skip to main content
Figure 2 | Journal of Translational Medicine

Figure 2

From: Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma

Figure 2

SLC22A18 expression in patients stratified by tumor grade and recurrence. (A) Semiquantitative analysis of SLC22A18 immunohistochemical staining in low grade (WHO I-II) glioma and high grade (WHO III-IV) glioma. (B) Semiquantitative analysis of SLC22A18 immunohistochemical staining in gliomas which recurred and those which did not recur within six months after surgery, P values compare overall SLC22A18 expression in each group.

Back to article page